汇宇制药-W
(688553)
| 流通市值：60.02亿 | | | 总市值：74.00亿 |
| 流通股本：3.44亿 | | | 总股本：4.24亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 269,206,581.35 | 998,144,952.02 | 741,750,405.84 | 453,118,838.7 |
| 营业收入 | 269,206,581.35 | 998,144,952.02 | 741,750,405.84 | 453,118,838.7 |
| 二、营业总成本 | 241,878,348.21 | 923,789,392.55 | 685,551,126.24 | 429,857,375.39 |
| 营业成本 | 56,059,983.61 | 203,595,463.36 | 144,711,526.21 | 93,324,746.27 |
| 税金及附加 | 1,905,170.82 | 9,970,620.9 | 5,643,926.25 | 4,173,827.78 |
| 销售费用 | 86,603,675.57 | 359,230,759.2 | 272,034,014.01 | 173,514,766.45 |
| 管理费用 | 27,757,911.11 | 97,058,090.21 | 64,089,471.19 | 41,580,805.16 |
| 研发费用 | 66,821,499.28 | 302,705,012.35 | 231,620,158.48 | 149,419,089.98 |
| 财务费用 | 2,730,107.82 | -48,770,553.47 | -32,547,969.9 | -32,155,860.25 |
| 其中:利息费用 | 3,346,891.97 | 9,781,566.85 | 6,675,992.28 | 5,269,676.79 |
| 其中:利息收入 | 12,924,454.53 | 53,050,928.95 | 28,997,397.33 | 22,672,078.36 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -27,686,556.96 | -167,003,663.92 | -160,998,824.61 | -146,324,714.95 |
| 加:投资收益 | 7,584,604 | 477,465.87 | 3,332,115.82 | 3,029,759.73 |
| 资产处置收益 | - | 1,887.15 | 1,887.15 | 1,887.15 |
| 资产减值损失(新) | -1,966,016.88 | -5,406,404.61 | -1,467,728.97 | 102,518.99 |
| 信用减值损失(新) | 928,124.51 | -2,573,927.9 | -1,416,397.06 | -300,923.45 |
| 其他收益 | 9,802,246.24 | 33,924,260.17 | 27,040,728.9 | 13,881,937.44 |
| 四、营业利润 | 15,990,634.05 | -66,224,823.77 | -77,308,939.17 | -106,348,071.78 |
| 加:营业外收入 | 1,122,357.74 | 2,897,450.29 | 1,827,481.94 | 1,388,146.7 |
| 减:营业外支出 | 603,475.34 | 985,463.93 | 803,052.14 | 44,972.19 |
| 五、利润总额 | 16,509,516.45 | -64,312,837.41 | -76,284,509.37 | -105,004,897.27 |
| 减:所得税费用 | -5,210,470.69 | -33,765,083.27 | -21,214,658.68 | -21,409,443.12 |
| 六、净利润 | 21,719,987.14 | -30,547,754.14 | -55,069,850.69 | -83,595,454.15 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 21,719,987.14 | -30,547,754.14 | -55,069,850.69 | -83,595,454.15 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 21,869,139.53 | -24,961,496.76 | -50,804,666 | -80,720,507.81 |
| 少数股东损益 | -149,152.39 | -5,586,257.38 | -4,265,184.69 | -2,874,946.34 |
| 扣除非经常损益后的净利润 | 30,868,465.47 | 85,090,444.94 | 79,560,578.61 | 48,073,129.6 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | -0.06 | -0.12 | -0.19 |
| (二)稀释每股收益 | 0.05 | -0.06 | -0.12 | -0.19 |
| 八、其他综合收益 | 622,982.18 | -1,957,391.72 | -2,111,898.33 | -2,483,729.31 |
| 归属于母公司股东的其他综合收益 | 622,982.18 | -1,957,391.72 | -2,111,898.33 | -2,483,729.31 |
| 九、综合收益总额 | 22,342,969.32 | -32,505,145.86 | -57,181,749.02 | -86,079,183.46 |
| 归属于母公司股东的综合收益总额 | 22,492,121.71 | -26,918,888.48 | -52,916,564.33 | -83,204,237.12 |
| 归属于少数股东的综合收益总额 | -149,152.39 | -5,586,257.38 | -4,265,184.69 | -2,874,946.34 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-30 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |